![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Il trattamento del carcinoma del surrene
Il trattamento di elezione nei pazienti affetti da carcinoma del cortico-surrene (ACC) è rappresentato dalla chirurgia che ha un impatto favorevole sulla sopravvivenza globale. La diagnosi di ACC è tuttavia ra...
-
Article
Metronomic Therapy Concepts in the Management of Adrenocortical Carcinoma
Metronomic chemotherapy is the administration of cytotoxic drugs at low doses, on a frequent or continuous schedule, with no extended interruption. This treatment approach can target tumor cells indirectly sin...
-
Article
Diagnosi e terapia del carcinoma corticosurrenalico
Il carcinoma corticosurrenalico (CCS) è un tumore raro e molto aggressivo. Al momento attuale non sono stati individuati approcci terapeutici personalizzati, ad eccezione della terapia con mitotane guidata dal...
-
Article
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome
Androgen deprivation therapy (ADT) leads to important changes in body composition. No data are currently available about the relationship between these treatment-related changes and patient outcome. Using dual...
-
Article
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a signif...
-
Article
Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients
-
Article
Palbociclib inhibits proliferation of human adrenocortical tumor cells
-
Article
Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma
-
Article
In vitro antitumor activity of progesterone in human adrenocortical carcinoma
The management of patients with adrenocortical carcinoma (ACC) is challenging. As mitotane and chemotherapy show limited efficacy, there is an urgent need to develop therapeutic approaches. The aim of this stu...
-
Article
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents
-
Article
Antineoplastic activity of artemisinin in adrenocortical carcinoma
-
Article
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarke...
-
Article
Should everolimus be stopped after radiological progression in metastatic insulinoma? A “cons” point of view
Insulinoma is a rare pancreatic neuroendocrine tumor (pNET) potentially associated with severe hypoglycaemic crisis. The great majority of these tumors are benign. In patients with metastatic malignant insulin...
-
Article
Maintenance everolimus beyond progression in pancreatic NET to control insulinoma syndrome
-
Chapter
Cancer of the Thyroid
Thyroid cancers are the most frequent endocrine neoplasms whose incidence is globally increasing. Thyroid carcinomas basically derived from follicular (papillary, follicular, anaplastic and poorly differentiat...
-
Chapter
Cancer of the Adrenal Gland
The embryology and physiology of the adrenal gland is complex, and two different tumors may arise according to whether the cell transformation occurs in the cortex or medulla. Most of these tumors are benign, ...
-
Article
Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy
-
Article
Open AccessDifferent management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
Pediatric and adult adrenocortical carcinomas differ in many respects but treatment is often similar in both age groups. The Journal of Clinical Oncology recently published the results of a risk-stratified single...
-
Article
Open AccessSupportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite...
-
Article
Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1–2, 2021